ALZ — Alzinova AB Share News
0.000.00%
Last trade - 00:00- SEK148.49m
- SEK135.99m
Brief: Alzinova Confirms Positive Phase 1B Results With Alz-101 Against Alzheimer's
Brief: Alzinova's CFO Håkan Skogström To Retire Next Year
Brief: Alzinova: Positive Phase 1B Results With Vaccine Candidate Alz-101
Brief: Alzinova Q3 Loss After Financial Items Widens To SEK 3.5 Mln
Brief: Alzinova Gets Positive Response From European Medicines Agency EMA
Brief: Alzinova Partners With Polypeptide
Brief: Alzinova Q2 EPS at SEK -0.1
Brief: Alzinova Progresses Following Positive Pre-Ind Meeting With FDA
Brief: Alzinova Submits Request For Pre-IND Meeting With FDA, Applies For EMA Scientific Advice
Brief: Alzinova Starts Extension Part Of Phase 1b Study With ALZ-101
Brief: Alzinova Q1 Loss After Financial Items Widens To SEK 4.3 Mln
Brief: Alzinova Q1 EPS at SEK -0.09
Brief: Alzinova Chief Medical Officer To Leave Company
Brief: Alzinova Files Patent Application For Alz-201 Antibody
Brief: Alzinova: New Positive Safety Review Of Phase 1B Study For ALZ-101 Vaccine
Brief: Alzinova Board Proposes No Dividends To Be Paid For 2022
Brief: Alzinova Q3 Loss After Financial Items Widens To SEK 2.8 Mln
Brief: Alzinova Announces New Positive Safety Review Of Its Phase 1B Study In Alzheimer's Disease
Brief: Alzinova Q2 Loss At SEK 3.3 Mln